• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在广泛代谢型土耳其患者中,针对CYP2C19基因多态性,在初始阶段使用高剂量奥美拉唑和阿莫西林的改良序贯幽门螺杆菌根除疗法无效。

Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective.

作者信息

Sezgin Orhan, Barlas I Omer, Uçbilek Enver, Yengel Emre, Altintaş Engin

出版信息

Acta Gastroenterol Belg. 2014 Mar;77(1):3-7.

PMID:24761684
Abstract

AIM

To investigate whether the sequential therapy composed of high dose omeprazole and high dose amoxicillin in the first step was effective in eradication of H. pylori and whether there was a relation between effectiveness of the therapy and CYP2C19 gene polymorphism.

METHOD

134 dyspeptic patients with H. pylori were administered a modified sequential therapy composed of omeprazole 40 mg t.i.d. and amoxicillin 1000 mg t.i.d, for the first five days followed by omeprazole 20 mg b.d., metronidazole 500 mg t.i.d. and tetracycline 500 mg t.i.d, for the next five days. CYP2C19 genotype status was determined in patients. Hp eradication status was investigated by C14 UNT four weeks after treatment.

RESULTS

The eradication rates were 64.9% in ITT and 74.3% in PP analysis. In subgroup analyses, eradication rates were 73.8% and 60.8% (p: 0.145) in ITT for peptic ulcer and non-ulcer dyspepsia patients respectively and 86.1% and 69.1% (p: 0.052) in PP analysis for peptic ulcer and non-ulcer dyspepsia patients respectively. The difference was not significant. As for the CYP2C19 gene status, 81.5% of the patients had HoEM and 17.3% of the patients had HeEM, and eradication rates were 72% and 75% in ITT analysis for HoEM and HeEM respectively (p: 0.803) and 73.9% and 85.7% in PP analysis for HoEM and HeEM respectively (p: 0.347). There was not a significant difference in H. pylori eradication rates between the two groups.

CONCLUSION

This modified high-dose sequential therapy was ineffective in a Turkish sample, nearly all of whom had EM in terms of CYP2C19 gene status.

摘要

目的

探讨第一步采用大剂量奥美拉唑和大剂量阿莫西林的序贯疗法根除幽门螺杆菌是否有效,以及该疗法的有效性与CYP2C19基因多态性之间是否存在关联。

方法

对134例幽门螺杆菌感染的消化不良患者采用改良序贯疗法,前五天给予奥美拉唑40毫克每日三次和阿莫西林1000毫克每日三次,接下来五天给予奥美拉唑20毫克每日两次、甲硝唑500毫克每日三次和四环素500毫克每日三次。测定患者的CYP2C19基因型状态。治疗四周后通过C14尿素呼气试验调查幽门螺杆菌根除情况。

结果

意向性分析(ITT)中的根除率为64.9%,符合方案分析(PP)中的根除率为74.3%。在亚组分析中,消化性溃疡患者和非溃疡性消化不良患者在ITT中的根除率分别为73.8%和60.8%(p:0.145),在PP分析中分别为86.1%和69.1%(p:0.052)。差异无统计学意义。至于CYP2C19基因状态,81.5%的患者为纯合野生型(HoEM),17.3%的患者为杂合野生型(HeEM),在ITT分析中,HoEM和HeEM的根除率分别为72%和75%(p:0.803),在PP分析中分别为73.9%和85.7%(p:0.347)。两组之间幽门螺杆菌根除率无显著差异。

结论

在一个土耳其样本中,这种改良的大剂量序贯疗法无效,该样本中几乎所有患者在CYP2C19基因状态方面均为野生型。

相似文献

1
Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective.在广泛代谢型土耳其患者中,针对CYP2C19基因多态性,在初始阶段使用高剂量奥美拉唑和阿莫西林的改良序贯幽门螺杆菌根除疗法无效。
Acta Gastroenterol Belg. 2014 Mar;77(1):3-7.
2
Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.奥美拉唑剂量和细胞色素 P450 2C19 基因型在接受奥美拉唑-阿莫西林双联疗法根除幽门螺杆菌治疗的患者中的作用。
Pharmacotherapy. 2011 Mar;31(3):227-38. doi: 10.1592/phco.31.3.227.
3
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.CYP2C19基因分型差异对质子泵抑制剂、阿莫西林和克拉霉素三联疗法治疗幽门螺杆菌感染治愈率的影响。
Clin Pharmacol Ther. 2001 Mar;69(3):158-68. doi: 10.1067/mcp.2001.113959.
4
[A 10-day sequential therapy for eradication of Helicobacter pylori infection in children].[一种用于根除儿童幽门螺杆菌感染的10天序贯疗法]
Zhonghua Er Ke Za Zhi. 2012 Aug;50(8):563-7.
5
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.埃索美拉唑40毫克,每日两次,用于三联疗法以及与CYP2C19代谢相关的幽门螺杆菌根除疗效。
Aliment Pharmacol Ther. 2005 Feb 1;21(3):283-8. doi: 10.1111/j.1365-2036.2005.02281.x.
6
Effect of omeprazole and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the healing of duodenal ulcer: comparison with a historical control.奥美拉唑、阿莫西林联合甲硝唑对幽门螺杆菌根除及十二指肠溃疡愈合的影响:与历史对照比较
Hepatogastroenterology. 1999 Jul-Aug;46(28):2358-62.
7
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.雷贝拉唑三联疗法治疗幽门螺杆菌感染与CYP2C19基因分型的相关性
Korean J Gastroenterol. 2003 Dec;42(6):468-75.
8
Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin.阿奇霉素、奥美拉唑和阿莫西林三联疗法在根除幽门螺杆菌方面非常有效:与奥美拉唑加阿莫西林的对照试验。
Am J Gastroenterol. 1996 Feb;91(2):258-63.
9
Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia?对于治疗消化性溃疡和非溃疡性消化不良中的幽门螺杆菌感染,奥美拉唑、阿莫西林和克拉霉素联合使用12天是否比6天更有效?
Hepatogastroenterology. 2001 Sep-Oct;48(41):1383-8.
10
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.CYP2C19、MDR1 和白细胞介素 1-B 基因变异对泮托拉唑、阿莫西林和甲硝唑三联疗法根除幽门螺杆菌感染的影响。
Eur J Clin Pharmacol. 2010 Jul;66(7):681-7. doi: 10.1007/s00228-010-0818-1. Epub 2010 Apr 8.

引用本文的文献

1
Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies.土耳其幽门螺杆菌根除的标准三联疗法:十年研究的系统评价与荟萃分析
Turk J Gastroenterol. 2019 May;30(5):420-435. doi: 10.5152/tjg.2019.18693.
2
Safety assessment of omeprazole use: a review.奥美拉唑使用的安全性评估:一项综述。
Sao Paulo Med J. 2018 Nov-Dec;136(6):557-570. doi: 10.1590/1516-3180.2018.0019220318.